PAIN THERAPEUTICS WKN: A2PGL8 ISIN: US14817C1071 Kürzel: SAVA Forum: Aktien Thema: Hauptdiskussion

https://www.cassavasciences.com/static-files/bf7b91e1-e681-4ce9-be05-fae00e3d642e

Anbei das März Update. Ab Q3 2023 wird es dann wohl richtig spannend hier

Das sind doch gute News

Cassava Sciences Inc Has No Financial Exposure To Silicon Valley Bank Or Silvergate Bank https://www.cassavasciences.com/node/16281/html ... Cassava Sciences, Inc. confirmed today that it has no financial exposure to Silicon Valley Bank or Silvergate Bank. J.P. Morgan serves as Cassava Sciences’ principal commercial bank. ...

Stehen irgendwelche News bald an? Zwischenergebnisse oder ähnliches?

Alle positiven Nachrichten werden gleich wieder verkauft unglaublich

Wenn man vom Teufel spricht 😂

Insider Buy https://www.sec.gov/Archives/edgar/data/1069530/000106953023000011/xslF345X03/certent-form4.xml

Gibt's irgwie mal wieder news etc ? 😁

Cassava Sciences GAAP EPS of -$0.47 beats by $0.11 https://seekingalpha.com/news/3941853-cassava-sciences-gaap-eps-of-0_47-beats-0_11 • Cassava Sciences press release (NASDAQ:SAVA): Q4 GAAP EPS of -$0.47 beats by $0.11. • At December 31, 2022, cash and cash equivalents were $201 million, compared to $233.4 million at December 31, 2021, with no debt. Year-end cash balance included net proceeds of $47.3 million from the sale of 1.7 million shares of common stock completed in November 2022. • Net cash use for operations for the first half of 2023 is expected to be approximately $45 to $50 million, driven primarily by expenses for our clinical program in Alzheimer’s disease.

https://www.globenewswire.com/news-release/2023/02/28/2617230/8339/en/Cassava-Sciences-Reports-Full-year-2022-Financial-Results-and-Operating-Updates.html

https://www.instagram.com/reel/CokiE0IIwDE/?igshid=YmMyMTA2M2Y=

🤷‍♂️🤢🤬

Warum heute der Absturz?

953 Alzheimer’s Patients Are Now Enrolled Across Phase 3 Studies Both Phase 3 Studies Have Passed the Halfway Mark for Enrollment Goal Is to Complete Enrollment for Both Phase 3 Studies by Year-End 2023 AUSTIN, Texas, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced an update on patient enrollment for its on-going Phase 3 clinical studies of simufilam for the treatment of Alzheimer’s disease dementia. Simufilam, an oral drug, is Cassava Sciences’ proprietary lead drug candidate. James W. Kupiec, MD, Chief Medical Officer of Cassava Sciences, commented, “We are pleased with the recent pickup in the pace of patient enrollment with our Phase 3 studies, which are designed to evaluate the safety and efficacy of simufilam in patients with Alzheimer’s disease.” A total of 953 Alzheimer’s patients are now enrolled across Cassava Sciences’ Phase 3 studies. For each Phase 3 study, patient enrollment has passed the halfway mark of the target patient enrollment. The enrollment target for both (not each) Phase 3 clinical studies is approximately 1,750 patients with mild-to-moderate Alzheimer’s disease who also meet other study eligibility criteria. There are no interim analyses in Cassava Sciences’ Phase 3 studies. “We anticipate the completion of patient enrollment for both of our Phase 3 studies by year-end 2023,” said Remi Barbier, Present & CEO. “Based on recent enrollment trends, we think this is a realistic expectation for completing patient enrollment.”

Dankeschön 😄